MRC Technology and IPS-CAS in antibody drug discovery collaboration
Posted: 6 April 2016 | Victoria White | No comments yet
The parties created IPS-MRCT Joint Centre for Therapeutic Antibodies in order to combine their expertise in research and development…
Standing (left) Duan Ziyuan, Deputy Director, Bureau of Science and Technology for Development, Chinese Academy of Sciences; Seif Usher, China Regional Director, Life Sciences, Health and Social Care, UK Trade & Investment; seated (left) Dr Dave Tapolczay, Chief Executive, MRC Technology and Tang Hong, Director Institute Pasteur of Shanghai
MRC Technology and Institut Pasteur of Shanghai, Chinese Academy of Sciences (IPS-CAS) have signed a collaboration agreement to develop new therapeutic antibodies from research originating in China.
IPS-CAS is well regarded for their cutting-edge research in infectious diseases and capability generating antibodies and MRC Technology has proven expertise in progressing promising research towards the clinic. The parties created IPS-MRCT Joint Centre for Therapeutic Antibodies in order to combine their expertise in research and development, intellectual property (IP) protection and management, and commercial acumen for more precise and efficient technology transfer.
Drug Target Review has just announced the launch of its NEW and EXCLUSIVE report examining the evolution of AI and informatics in drug discovery and development.
In this 63 page in-depth report, experts and researchers explore the key benefits of AI and informatics processes, reveal where the challenges lie for the implementation of AI and how they see the use of these technologies streamlining workflows in the future.
Also featured are exclusive interviews with leading scientists from AstraZeneca, Auransa, PolarisQB and Chalmers University of Technology.
Professor Sun Bing, the Director of IPS-MRCT Joint Centre for Therapeutic Antibodies commented on the collaboration between IPS-CAS and MRC Technology: “The promise of immune check-point antibodies and broadly neutralising antibodies against pathogens brings a boom in research and research development across the world, which makes this collaboration all the more significant and important.”
Dr Dave Tapolczay, Chief Executive, MRC Technology, added: “MRC Technology uses the potential of science to change lives. Our projects have led to several approved drugs which are improving patients’ lives across the world. Biomedical research is flourishing in China and we are pleased to work with IPS to progress the science towards worldwide benefit.”
The Chinese Academy of Sciences is proposing to set up a new centre to manage intellectual property and will also draw on MRC Technology’s expertise in IP development, protection and management in this venture.
Related topics
Antibodies, Antibody Discovery
Related organisations
MRC Technology
